Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy

Figures & data

Table 1 Sociodemographical data of the whole study group

Subjects	MMSE	UPDRS/56	NPI/144	Age	Education
51	19.9	35.2	57.6	70.4	6.4

Note: Age and education are expressed in years.

Abbreviations: MMSE, mini–mental state examination; NPI, Neuropsychiatric Inventory; UPDRS, Unified Parkinson’s Disease Rating Scale.

Table 2 Number of subjects and clinical characteristics at baseline, T6, T12, and T18 follow-up

	Baseline	T6	T12	T18
Subjects	51	45 (6)	30 (1)	21 (0)
MMSE	19.9 (±1.2)	18.9 (±2.3)	17.2 (±0.4)	14.1 (±1.8)
UPDRS	35.2 (±2.2)	28.1 (±3.1)	26.4 (±2.9)	25.5 (±4.3)
NPI	57.6 (±2.4)	52.1 (±3.09)	51.5 (±1.5)	38.8 (±0.9)
RTG dosage	ND	3.2 (±0.2)	4.2 (±0.5)	5.1 (±1.1)

Note: The number of subjects that dropped out are shown within the parentheses.

Abbreviations: MMSE, mini–mental state examination; ND, no data; NPI, Neuropsychiatric Inventory; RTG, rotigotine; UPDRS, Unified Parkinson’s Disease Rating Scale; T, time.

Figure 1 ANOVA results for UPDRS score.

Abbreviations: ANOVA, analysis of variance; UPDRS, Unified Parkinson’s Disease Rating Scale; T, time.

Figure 2 ANOVA results for NPI score.

Abbreviations: ANOVA, analysis of variance; NPI, Neuropsychiatric Inventory; T, time.

Figure 3 ANOVA results for MMSE score.

Abbreviations: ANOVA, analysis of variance; MMSE, mini–mental state examination; T, time.